• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference?

作者信息

Bolek Tomáš, Samoš Matej, Škorňová Ingrid, Schnierer Martin, Lipták Peter, Bánovčin Peter, Urban Lukáš, Staško Ján, Kubisz Peter, Galajda Peter, Mokán Marián

机构信息

Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovak Republic.

National Centre of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.

出版信息

Eur J Clin Pharmacol. 2019 Jun;75(6):875-877. doi: 10.1007/s00228-019-02647-8. Epub 2019 Feb 12.

DOI:10.1007/s00228-019-02647-8
PMID:30747244
Abstract
摘要

相似文献

1
Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference?接受奥美拉唑与泮托拉唑治疗的房颤患者中达比加群的血药浓度：有差异吗？
Eur J Clin Pharmacol. 2019 Jun;75(6):875-877. doi: 10.1007/s00228-019-02647-8. Epub 2019 Feb 12.
2
The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etexilate Plasma Levels in Patients With Atrial Fibrillation: A Washout Study.质子泵抑制剂停药对房颤患者达比加群酯血浆水平的影响：一项洗脱研究。
J Cardiovasc Pharmacol. 2020 Apr;75(4):333-335. doi: 10.1097/FJC.0000000000000791.
3
The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation.质子泵抑制剂对房颤患者达比加群水平的影响。
Am J Ther. 2019 May/Jun;26(3):e308-e313. doi: 10.1097/MJT.0000000000000599.
4
Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function.达比加群酯75毫克每日两次在非瓣膜性心房颤动且肾功能严重受损患者中的药代动力学/药效学研究
J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):399-406. doi: 10.1177/1074248418769167. Epub 2018 Apr 25.
5
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.奥美拉唑与泮托拉唑对150毫克氯吡格雷高维持剂量影响的比较：PACA（质子泵抑制剂与氯吡格雷关联）前瞻性随机研究。
J Am Coll Cardiol. 2009 Sep 22;54(13):1149-53. doi: 10.1016/j.jacc.2009.05.050.
6
Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.质子泵抑制剂奥美拉唑和泮托拉唑对文拉法辛细胞色素 P450 介导的代谢的影响。
Clin Pharmacokinet. 2018 Jun;57(6):729-737. doi: 10.1007/s40262-017-0591-8.
7
Left subconjunctival hemorrhage · renal dysfunction · international normalized ratio of 4.5 · Dx?左结膜下出血·肾功能不全·国际标准化比值为4.5·诊断是什么？
J Fam Pract. 2015 Oct;64(10):E3-4.
8
Proton pump inhibitors and osteoporosis risk: exploring the role of TRPM7 channel.质子泵抑制剂与骨质疏松风险：探索 TRPM7 通道的作用。
Eur J Clin Pharmacol. 2022 Jan;78(1):35-41. doi: 10.1007/s00228-021-03237-3. Epub 2021 Oct 29.
9
Use of Extracorporeal Techniques in the Removal of Dabigatran.体外技术在达比加群清除中的应用
Am J Ther. 2016 Mar-Apr;23(2):e485-8. doi: 10.1097/MJT.0000000000000082.
10
Uninterrupted dabigatran versus warfarin in the treatment of intracardiac thrombus in patients with non-valvular atrial fibrillation.非瓣膜性心房颤动患者中心内血栓治疗中达比加群与华法林的不间断治疗对比
Int J Cardiol. 2015;190:63-6. doi: 10.1016/j.ijcard.2015.04.104. Epub 2015 Apr 16.

引用本文的文献

1
Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice.直接口服抗凝剂（DOACs）的药物相互作用：从药理学到临床实践
Pharmaceutics. 2022 May 24;14(6):1120. doi: 10.3390/pharmaceutics14061120.

本文引用的文献

1
How to proceed with long-term anticoagulation in patient after total gastrectomy and atrial fibrillation?全胃切除术后合并心房颤动的患者如何进行长期抗凝治疗？
Eur J Clin Pharmacol. 2019 Feb;75(2):285-286. doi: 10.1007/s00228-018-2571-9. Epub 2018 Oct 9.
2
Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study.质子泵抑制剂是否会改变接受 Xabans 治疗的房颤患者的治疗后抗 Xa 活性？一项初步研究。
J Thromb Thrombolysis. 2019 Jan;47(1):140-145. doi: 10.1007/s11239-018-1748-5.
3
Proton Pump Inhibition in Patients Treated With Novel Antithrombotic Drugs: Should We Worry About Thrombosis?
质子泵抑制剂在新型抗血栓药物治疗患者中的应用：我们是否应该担心血栓形成？
J Cardiovasc Pharmacol. 2018 Jul;72(1):71-76. doi: 10.1097/FJC.0000000000000593.
4
Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation.质子泵抑制剂对日本非瓣膜性心房颤动患者血液中达比加群浓度的影响。
J Arrhythm. 2017 Dec;33(6):619-623. doi: 10.1016/j.joa.2017.07.013. Epub 2017 Oct 12.
5
The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation.质子泵抑制剂对房颤患者达比加群水平的影响。
Am J Ther. 2019 May/Jun;26(3):e308-e313. doi: 10.1097/MJT.0000000000000599.
6
The potential drug-drug interaction between proton pump inhibitors and warfarin.质子泵抑制剂与华法林之间潜在的药物相互作用。
Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1337-40. doi: 10.1002/pds.3881. Epub 2015 Sep 23.
7
In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors.达比加群与质子泵抑制剂之间药物相互作用的体外和体内评估。
Fundam Clin Pharmacol. 2015 Dec;29(6):604-14. doi: 10.1111/fcp.12154. Epub 2015 Oct 7.
8
Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study.胃保护剂预防达比加群相关胃肠道出血的效果：一项基于人群的研究。
Gastroenterology. 2015 Sep;149(3):586-95.e3. doi: 10.1053/j.gastro.2015.05.002. Epub 2015 May 8.
9
Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation.使用Hemoclot（®）凝血酶抑制剂检测法监测心房颤动患者的达比加群治疗情况。
J Thromb Thrombolysis. 2015 Jan;39(1):95-100. doi: 10.1007/s11239-014-1125-y.
10
Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.质子泵抑制剂的药代动力学药物相互作用概况：最新进展。
Drug Saf. 2014 Apr;37(4):201-11. doi: 10.1007/s40264-014-0144-0.